Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children

Erika Wallender; Ali Mohamed Ali; Emma Hughes; Abel Kakuru; Prasanna Jagannathan; Mary Kakuru Muhindo; Bishop Opira; Meghan Whalen; Liusheng Huang; Marvin Duvalsaint; Jenny Legac; Moses R. Kamya; Grant Dorsey; Francesca Aweeka; Philip J. Rosenthal; Rada M. Savic

doi:10.1038/s41467-021-27051-8

Nature Communications (Nov 2021)

Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children

Erika Wallender,
Ali Mohamed Ali,
Emma Hughes,
Abel Kakuru,
Prasanna Jagannathan,
Mary Kakuru Muhindo,
Bishop Opira,
Meghan Whalen,
Liusheng Huang,
Marvin Duvalsaint,
Jenny Legac,
Moses R. Kamya,
Grant Dorsey,
Francesca Aweeka,
Philip J. Rosenthal,
Rada M. Savic

Affiliations

Erika Wallender: Department of Clinical Pharmacy, University of California, San Francisco
Ali Mohamed Ali: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Emma Hughes: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Abel Kakuru: Infectious Diseases Research Collaboration
Prasanna Jagannathan: Department of Medicine, Stanford University
Mary Kakuru Muhindo: Infectious Diseases Research Collaboration
Bishop Opira: Infectious Diseases Research Collaboration
Meghan Whalen: Department of Clinical Pharmacy, University of California, San Francisco
Liusheng Huang: Department of Clinical Pharmacy, University of California, San Francisco
Marvin Duvalsaint: Department of Medicine, University of California, San Francisco
Jenny Legac: Department of Medicine, University of California, San Francisco
Moses R. Kamya: Infectious Diseases Research Collaboration
Grant Dorsey: Department of Medicine, University of California, San Francisco
Francesca Aweeka: Department of Clinical Pharmacy, University of California, San Francisco
Philip J. Rosenthal: Department of Medicine, University of California, San Francisco
Rada M. Savic: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco

DOI: https://doi.org/10.1038/s41467-021-27051-8
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Intermittent preventive treatment with dihydroartemisinin-piperaquine (DP) is protective in children against malaria. Here, the authors analyze plasma drug concentration, malaria incidence, and drug resistance markers from a clinical trial in Uganda and determine the optimal DP dosing regimen.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal